Association between human leucocyte antigen-DO polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.
Association between human leucocyte antigen-DO polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study.
复制标题
中国人群1型丙型肝炎病毒感染中人类白细胞抗原-DO多态性与干扰素/利巴韦林治疗反应之间的关联：一项前瞻性研究
DOI：
10.1136/bmjopen-2017-019406
复制
发表时间：
2018-04-12
期刊：
影响因子：
2.9
通讯作者：
Yu R
中科院分区：
文献类型：
--
作者：
Yao Y;Liu M;Zang F;Yue M;Xia X;Feng Y;Fan H;Zhang Y;Huang P;Yu R
目的研究丙型肝炎病毒（HCV）感染后，人类白细胞抗原-DO（HLA-DO）基因在HCV治疗反应中的作用。本研究旨在探讨HLA-DO基因单核苷酸多态性（single nucleotide polymorphisms，SNPs）在HCV治疗应答中的作用。所有患者均于2011年1月至2016年9月期间从中国江苏省句容市人民医院招募。研究对象346例慢性丙型肝炎（CHC）患者接受了为期48周的聚乙二醇干扰素-α和利巴韦林（PEG IFN-α/RBV）治疗。所有患者均为既往有偿献血者。患者的入选标准如下：（1）未经治疗并接受PEG IFN-α/RBV治疗，（2）治疗前血清中存在HCV RNA超过6个月，（3）B肝炎（HBV）或HIV感染阴性，（4）无任何其他肝脏疾病。本研究所有受试者均为中国汉族人群，感染HCV基因型1b，接受PEG IFN-α皮下注射治疗，剂量为180 µg，每周1次，根据体重口服800-1000 mg/d RBV，持续48周。结果18个SNPs中HLA-DOA rs 1044429、HLA-DOB rs 2284191和rs 2856997与中国汉族人群HCV治疗应答相关。优势模型表明，携带rs 1044429 AA和rs 2284191 AA有利基因型的患者更有可能实现持续病毒学应答（SVR）（OR 1.99，95% CI 1.25 ~ 3.19; OR 2.71，95%CI 1.58 - 4.63），而携带rs 2856997 GG不利基因型的患者实现SVR的可能性较小（OR 0.48，95% CI 0.29至0.78）。结论rs 1044429、rs 2284191和rs 2856997基因变异是中国汉族人群HCV治疗应答的独立预测因子。
Objective The human leucocyte antigen-DO (HLA-DO) gene located in the HLA non-classical class-II region may play a role in treatment response to hepatitis C virus (HCV). This study was conducted to explore the role of single nucleotide polymorphisms (SNPs) in HLA-DO in responding to HCV therapy. Setting All patients were recruited between January 2011 and September 2016 from the Jurong People’s Hospital, Jiangsu Province, China. Participants A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV) treatment were enrolled in this study. All patients were former remunerated blood donors. The inclusion criteria for patients were as follows: (1) treatment-naive and treated with PEG IFN-α/RBV, (2) HCV RNA was present in serum for over 6 months before treatment, (3) negative for hepatitis B (HBV) or HIV infection and (4) lacked any other hepatic diseases. All participants in this study were Chinese Han population and infected with HCV genotype 1b and treated with subcutaneous PEG IFN-α at a dose of 180 µg once a week with the addition of 800–1000 mg/d RBV according to weight orally for 48 weeks. Results The SNPs HLA-DOA rs1044429 and HLA-DOB rs2284191 and rs2856997 of 18 SNPs were correlated with HCV treatment response in the Chinese Han population. The dominant model indicated that patients carrying favourable genotypes at rs1044429 AA and rs2284191 AA were more likely to achieve sustained virological response (SVR) (OR 1.99, 95% CI 1.25 to 3.19; OR 2.71, 95% CI 1.58 to 4.63, respectively), while patients carrying unfavourable genotypes at rs2856997 GG were less likely to achieve SVR (OR 0.48, 95% CI 0.29 to 0.78). Conclusion Genetic variations at rs1044429, rs2284191 and rs2856997 were independent predictors of HCV treatment response in the Chinese Han population.
登录
查看更多内容
影响因子：
2.4
作者：
Idrees M;Riazuddin S
通讯作者：
Riazuddin S
影响因子：
168.9
作者：
Gakidou, Emmanuela;Cowling, Krycia;Murray, Christopher J. L.
通讯作者：
Murray, Christopher J. L.
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
13.5
作者：
Bressler, BL;Guindi, M;Heathcote, J
通讯作者：
Heathcote, J
影响因子：
29.4
作者：
Rauch, Andri;Kutalik, Zoltan;Bochud, Pierre-Yves
通讯作者：
Bochud, Pierre-Yves